tradingkey.logo
tradingkey.logo
Search

Collplant Biotechnologies Ltd

CLGN
Add to Watchlist
0.440USD
+0.020+4.79%
Close 05/15, 16:00ETQuotes delayed by 15 min
5.63MMarket Cap
LossP/E TTM

Collplant Biotechnologies Ltd

0.440
+0.020+4.79%
View Detailed Chart
Intraday
1m
30m
1h
D
W
M
D

Today

+4.79%

5 Days

+9.35%

1 Month

+24.84%

6 Months

-77.73%

Year to Date

-68.59%

1 Year

-74.58%

Key Insights

Collplant Biotechnologies Ltd's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 177 out of 382 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as , with the highest price target at 11.00.In the medium term, the stock price is expected to trend down.Despite a strong stock market performance and outperforming fundamentals over the past month, the technicals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Collplant Biotechnologies Ltd's Score

Industry at a Glance

Industry Ranking
177 / 382
Overall Ranking
322 / 4482
Industry
Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Neutral

Collplant Biotechnologies Ltd Highlights

StrengthsRisks
CollPlant Biotechnologies Ltd, formerly known as Collplant Holdings Ltd, is a company dealing in aesthetic medicine and regenerative medicine based in Israel. The company provides products and technologies for broadly understood regenerative medicine, including tissue regeneration and organ production. The technology is based on plants and is based on the production of collagen type I (rhCollagen).
Growing
The company is in a growing phase, with the latest annual income totaling USD 2.37M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 2.37M.
Overvalued
The company’s latest PE is -0.47, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 1.89M shares, decreasing 10.36% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 17.60K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.99.

Analyst Rating

Based on 0 analysts
--
Current Rating
11.000
Target Price
+2527.18%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Collplant Biotechnologies Ltd News

More news coming soon, stay tuned...

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

Collplant Biotechnologies Ltd Info

CollPlant Biotechnologies Ltd, formerly known as Collplant Holdings Ltd, is a company dealing in aesthetic medicine and regenerative medicine based in Israel. The company provides products and technologies for broadly understood regenerative medicine, including tissue regeneration and organ production. The technology is based on plants and is based on the production of collagen type I (rhCollagen).
Ticker SymbolCLGN
CompanyCollplant Biotechnologies Ltd
CEORotem (Eran)
Websitehttps://www.collplant.com
KeyAI